挑战辉瑞!Alnylam的Amvuttra获批成为首个用于罕见心肌病的RNAi抑制剂

康可药研
Mar 21, 2025

本文仅供信息分享,不构成用药或治疗或投资推荐。因编辑水平有限,如有错误或不是最新信息感谢指出!来源:网络3月20日,Alnylam公司宣布,美国FDA已批准其RNAi 治疗药物vutrisiranA(商品名AMVUTTRA®) 的补充新药申请 (sNDA),用于治疗转甲状腺素蛋白淀粉样变性心肌病(ATTR-CM)。据其新闻稿,Alnylam宣布AMVUTTRA®(vutrisiran)获得FDA...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10